In vitro and in vivo efficacies of teicoplanin-loaded calcium sulfate for treatment of chronic methicillin-resistant Staphylococcus aureus osteomyelitis.
The in vitro and in vivo therapeutic efficacies of teicoplanin-loaded calcium sulfate (TCS; 10% [wt] teicoplanin) were investigated in a rabbit model of chronic methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. The in vitro elution characteristics of teicoplanin from TCS pellets were realized by carrying out an evaluation of the release kinetics, recovery rate, and antibacterial activity of the released teicoplanin. Chronic osteomyelitis was induced by inoculating 10(7) CFU of a MRSA strain into the tibial cavity of rabbits. After 3 weeks, the animals were treated by debridement followed by implantation of TCS pellets in group 1, calcium sulfate (CS) pellets alone in group 2, and intravenous (i.v.) teicoplanin (6 mg/kg of body weight every 12 h for three doses and then every 24 h up to 4 weeks) in group 3. Animals in group 4 were left untreated. After 6 weeks, the efficacy of the osteomyelitis treatment was evaluated by hematological, radiological, microbiological, and histological examinations. In vitro elution studies showed sustained release of teicoplanin at a therapeutic level over a time period of 3 weeks. The released teicoplanin maintained its antibacterial activity. In vivo, the best therapeutic effect was observed in animals treated with TCS pellets, resulting in significantly lower radiological and histological scores, lower positive rates of MRSA culture and bacterial load, and excellent bone regeneration compared with those treated by CS alone or i.v. teicoplanin, without any local or systemic adverse effects. TCS pellets are an effective alternative to i.v. teicoplanin for the treatment of chronic MRSA osteomyelitis, particularly because teicoplanin is delivered locally while the TCS pellets simultaneously promote bone defect repair.
Jia
Wei-Tao
WT
Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Jiaotong University, 600 Yishan Road, 200233 Shanghai, China.
Luo
Shi-Hua
SH
Zhang
Chang-Qing
CQ
Wang
Jian-Qiang
JQ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D002133:Calcium Sulfate / Q000494:pharmacology*; D016503:Drug Delivery Systems; D007275:Injections, Intravenous; D007958:Leukocyte Count; D055624:Methicillin-Resistant Staphylococcus aureus; D010019:Osteomyelitis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits; D011859:Radiography; D013203:Staphylococcal Infections / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D017334:Teicoplanin / Q000008:administration & dosage / Q000494:pharmacology*; D013977:Tibia / Q000000981:diagnostic imaging / Q000473:pathology
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D002133:Calcium Sulfate